Jain PharmaBiotech, June 2012, Pages: 639
relation to circadian rhythms
Implants for systemic delivery of anticancer drugs
Drug-eluting polymer implants
Angiogenesis and drug delivery to tumors
Antiangiogenesis strategies
Targeting tumor
Spectra Intelligence, Nov 2006, Pages: 367
development programmes and strategies, regulatory issues, and marketing challenges. Furthermore, market estimations fordrug classes are provided revealing those preclinical and clinical phase compounds that
BioPharm Reports (VennBio Ltd.), Jan 2009, Pages: 235
tumours that have been strongly implicated in cancer drug resistance. This chapter also includes proposed resistance mechanisms associated with CSCs, drugdiscoverystrategiesfor the targeting of these
Jain PharmaBiotech, June 2012, Pages: 276
tables and 25 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drugdiscovery and development. It is anticipated
John Wiley and Sons Ltd, Jan 2012, Pages: 680
Development of Therapeutic Agents Handbook A comprehensive look at current drugdiscovery and development methods and the roadmap for the future
Providing both understanding and guidance in
Datamonitor, April 2010, Pages: 243
significant development in oncology drugdiscovery
Classification of pipeline products
Angiogenesis inhibitor/vascular disrupting agents
Angiogenesis is known to be aberrant in tumor cell proliferation
The
Global Industry Analysts, Inc., Oct 2011, Pages: 897
Whammy Success 15
Patent Expiries of Branded Drugs to Trigger Generic Competition 16
Rising Investments Bring in New Troubles forDrug Makers 16
Emerging Challenges in Cancer Drug Development 16
Select
Lead Discovery, May 2005 for lead apoptosis modulators however the additional affects of HDAC inhibitors on cell cycle progression and angiogenesis should make successful HDAC inhibitors the partners of choice in combinatorial
Bioseeker, Dec 2005
: Phases in the drugdiscovery process
Figure 6: Analysis of Risk/Return for new chemical entities. Marketed between the years 1975 to 1984.
Figure 7: ADME/Tox Evaluation Process
4.3 List of Tables
Table
Informa Healthcare, Jan 2006, Pages: 170
Drug Targets for Breast Cancer Breast cancer is a complex heterogeneous disease characterised by uncontrolled growth and spread of abnormal cells. It is also very prevalent, with reports from the
Lead Discovery, Jan 2003, Pages: 65
, Urological conditions and cancer, Dr Goldhill was responsible for target identification and project development. Dr Goldhill is now CEO and chief analyst at LeadDiscovery and coordinates the identification of
